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more severely diseased population with more prior myocardial infarctions
(Mil, lower ejection fractions (H) and more 3 vessel or left main disease
(3 VD/LM). the angiographic success (Ang Succ) and residual stenosis (%DS
Post) have improved, without increased complications of a wave myocardial
infarction (0 MIl. emergency coronary bypass surgery (CABG) or in hospital
death (Death), In recent years new interventional devices (New Dev) have
been used in a large minority of patients, contributing to the improved re-
sults.
All comparisons between the 2 groups were not statistically significant.
In Conclusion: After S placement. irrespective of SVG age, 1) acute and late
angiographic results and restenosis rates were similar and 2) clinical results
(i.e. procedural success, major complications, target lesion revascularization
and 12-months event free survival) were comparable. Thus, unlike PTCA, in
appropriate SVG lesions, the favorable early and 12-month clinical outcomes
after S therapy are not diminished by advanced SVG age.
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1710-21 Coronary Stents Versus Balloon Angioplasty for
Aorto-Coronary Saphenous Vein Bypass Graft
Disease: Interim Results of a Randomized Trial
Fibrotic Ectatic p
Reference EEM area (mm2) 19.8 ± 7.3 18.6 ± 5.9 NS
Reference lumen area (mm2) 106 ± 4.4 106 ± 3.6 NS
Reference plaque area (mm2) 106 ± 100 8.0 ± 3.8 0.0052
Lesion site pre-intervention
Angiographic % diameter stenosis 63 ± 20 60 ± 22 NS
EEM area (mm 2) 16.1 ± 6.8 258 ± 10.6 <00001
Lumen area (mm2) 2.6 ± 2.2 3.6 ± 2.7 00016
Plaque + media area (mm2) 13.5 ± 6.4 21.9 ± 8.4 <00001
Arc of calcium n 61 ± 83 26 ± 54 0.001
Lesion/Reference plaque area 1.6 ± 0.7 3.1 ± 1.3 <0.0001
Lesion site post-intervention
Angiographic %diameter stenosis 17 ± 17 12 ± 19 0.0903
Lumen area (mm2) 67 ± 25 85 ± 2.9 0.0001
Follow-up angiographic %diameter stenosis 54 ± 33 35 ± 32 0.0329
16% of "fibrotic" had a lesion plaque area < reference. Importantly, (1)
post-intervention minimum lumen areas were significantly smaller in fibrotic
lesions, and (2) at follow-up the angiographic % diameter stenosis was signif-
icantly larger in fibrotic lesions. We Conclude: 40% of vein graft lesions may
be classified as "fibrotic". "Fibrotic" lesions have a decreased plaque bur-
den and more lesion-associated calcium. Lumen compromise results from
vessel retraction (?periadventitial fibrosis). In these lesions it may be more
difficult to achieve optimal final lumen dimensions resulting in more frequent
restenosis.
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1710-41 The Dimorphic Pathology of Vein Graft Lesions
Effects Acute Procedural and Late Angiographic
Outcomes
Gary S. Mintz, Jeffrey J. Popma, Augusto D. Pichard, Kenneth M. Kent, Lowell
F. Satler, S. Chiu Wong, Mun K. Hong, Jack A. Painter, Julie Mackenzie, Martin
B. Leon. Washington Hospital Center. Washington, DC
In an attempt to understand better the pathology and results of transcatheter
therapy of vein graft lesions, we performed intravascular ultrasound and
quantitative angiographic analysis of 244 nonostial vein graft lesions. Pre-
and post-intervention lesion site external elastic membrane (EEM), lumen,
and plaque cross-sectional areas, calcium, and % cross-sectional narrowing
(plaque/EEM area) were compared to a proximal reference site (most normal
looking cross-section within 10 mm proximal to the lesion). Lesions were di-
vided into two groups: 98 lesions with lesion EEM ::; reference ("fibrotic");
146 lesions with lesion EEM > reference ("ectatic"). There was no difference
in vein graft age, lesion length, or history of restenosis between the two
groups.
3:00
1710-5\ Progressive Deterioration in Late (2-Year) Clinical
Outcomes After Stent Implantation in Saphenous
Vein Grafts: The Multicenter JJIS Experience
Michael H. Sketch, Jr., S. Chiu Wong, Ya Chien Chuang, Harry R. Phillips,
Richard Heuser, Michael Savage, Richard S. Stack, Donald S. Bairn, Richard
A. Schatz, Martin B. Leon, JJIS Stent Investigators. Duke University Medical Center.
Durham, N. C.
Late clinical follow-up (after I-year) in patients treated with native coronary
stents demonstrates no further clinical events (death or MI) and rare delayed
target lesion revascularization (TLR = repeat PTCA or CABG). To examine
the long-term effects of stent placement in saphenous vein grafts (SVG), we
evaluated all follow-up clinical data in 661 consecutive patients (775 SVG le-
sionsl from the JJIS multicenter registry (17 sites). Baseline demographics
were pertinent for a high incidence of unstable angina (72%), heart failure
(22%). and high surgical risk status (49%). The mean SVG age was 9 ± 4
years, and the mean ejection fraction was 49 ± 14%. Overall procedure suc-
cess «50% residual stenosis without in-hospital death. MI, or CABG) was
92%, and subacute thrombosis was documented in 9 patients (14%).
SVG Age >4 years
34±0.6[6 ± 101
2.3 ± 1.3133 ± 361
28.7
97.0
1.7/04/09
54/9.5
77.0
SVG Age <4 years
33±0.717 ±121
2.1 ± 1.3142 ± 361
35.6
971
14/0/14
57/143
730
Angiographic results PICA Stent Clinical Events 1%) PICA Stent
Vessel diameter (mm) 3.21 3.18 Death 3.3 59
Baseline mid (mm) 0.98 093 O-wave MI 1.7 1.5
Final mid (mm) 2.12 2.85' Bypass Surgery 67 0"
Final % diam stenosis 33 12' Closure: S24 hrs 33 2.9
Procedure success (%) 85 96*>1: >24 hrs 1.7 0
, p < 0.01," p < 0.05 vs PICA
One or more major clinical events occurred in 11.7% of PTCA patients
vs 5.9% of Stent patients (p = ns). Crossover from assigned to alternative
therapy (including bypass surgery) was 13.3% for the PTCA group vs 1.5%
for the Stent group (p < 0.01). In conclusion, the preliminary findings of this
prospective trial indicate: (1) Elective stent placement in de novo saphenous
vein bypass graft lesions achieves a superior initial angiographic result com-
pared to balloon angioplasty; (2) Stents confer a salutary effect on early clini-
cal events with less frequent need for alterna1e therapies including coronary
bypass surgery.
Michael Savage, John Douglas, David Fischman, Sarah Fenton, Spencer King,
Carl Pepine, Steven Bailey, Paul Overlie, Jeffrey Werner, Martin Leon,
Richard Heuser, Jeffrey Brinker, Maurice Buchbinder, Richard Smalling,
David Snead, Randal Rake, Sharon Gebhardt, Richard Kerensky,
Thomas Wargovich, Sheldon Goldberg, SAVED Trial Investigators. Jefferson
Medical College, Philadelphia, PA
The purpose of this interim analysis of the SAVED Restenosis Trial was to
assess the acute results of balloon angioplasty (PTCA) and elective Palmaz-
Schatz coronary stent placement in the treatment of de novo venous bypass
graft lesions. As of August I, 1994, 128 patients (60 PTCA, 68 Stent) have
been enrolled at 13 centers. Baseline demographics were similar in both
groups. Mean graft ages in the PTCA and Stent groups were 9.8 ± 4.2 vs 9.7
± 4.5 years (p = ns). Initial angiographic results by core laboratory analysis
and clinical events from 0 to 30 days were as follows:
Angiographic Findings:
Final MLD (mm) [% stenosisl
Follow-up MLD 1% stenosis]
Restenosis (>50% stenosis)
Clinical Results: 1%)
Procedural success
In hospital deathlO-wave MIICABG
Follow-up target lesion CABG/PICA
12·month event free survival
1710-31 Stent Placement is Safe and Effective in the
Treatment of Older (>4 Years) Saphenous Vein Graft
Lesions
S. Chiu Wong, Ya Chien Chuang, Mun K. Hong, Augusto D. Pichard, Lowell
F. Saller, Kenneth M. Kent, Kathi Donovan, Donald S. Baim, Richard A. Schatz,
Martin B. Leon. Washington Hospital Center. Washington, DC
Conventional balloon angioplasty (PTCA) in older (>4 years) saphenous vein
grafts (SVGs) is associated with reduced procedural success and less favor-
able late clinical outcomes. To determine if stent (S) implantation neutral-
izes the adverse effects of SVG age on clinical events, we analyzed the early
and late results of 617 consecutive pts from the Palmaz-Schatz SVG S reg-
istry. In 69 pts (13.3%), SVG age was ::;4 (mean 2.1 ± 1.3) years and in 448
pts (86.7%), SVG age was >4 (mean 9.9 ± 3.5) years. There were no sig-
nificant differences in pt demographics and lesion characteristics between
the 2 groups. Procedural success was defined as successful S deployment
with <50% residual stenosis without major complications (death/ a-wave
Mil CABG). Follow-up angiograms were obtained in 63% of pts with SVG
SO 4 years and in 60% of pts with SVG > 4 years. MLD = minimal lumen
diameter.
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Actuarial follow-up event rates:
Events 6-months
- Death (%) 5
-MI(%) 7
- CABG (%) 7
- PTCA(%} 6
- Event-free survival (%) 75
12-months
8
8
9
8
67
24-months
14
8
12
12
55
revascularization (PTCA or CABG). Revascularization data were collected on
both the original target vessel and non-target vessels. The event free survival
curve for all patients shows Angiopeptin to significantly (p = 0.046) decrease
the clinical events compared to placebo. If non-target vessels are included
the improved event free survival is maintained (p = 0.0421. This significant
decrease in clinical event rate was already obtained at 6 months (p = 0.034,
odds ratio = 0.66, 95% confidence interval 0.45-0.97).
Event-free survival ~ freedom from death, MI. CABG or PTCA TVR TVR + non-TVR
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Recombinant-hirudin (CGP 39 393) Reduces the
Incidence of Major Adverse Cardiac Events,
Reported within the First 96 Hours Post-Angioplasty
in Unstable Patients (Braunwald Classification)
Pre-treated by Heparin
Patrick W Serruys, Keith AA Fox, Jean-Paul R. Herrman, Doris Bach 1,
Philip Close 1, Jaap W Deckers, HELVETICA investigators. Thoraxcentrum. Erasmus
University, Rotterdam, The Netherlands; 1 Ciba-Geigy Ltd, Bas/e, Switzerland
Background: r-Hirudin (Hir). an antithrombin may prevent thrombosis post
angioplasty thereby reducing early thrombotic events and late restenosis.
Methods: 1141 patients were prospectively randomized to 1) 10,OOOIU
heparin bolus + 15 IU/kg/hr iv heparin 24 hrs + sc placebo (HEP), or 2) Hir 40
mg bolus + 0.2 mg/kg/hr Hir iv 24 hrs + sc placebo (HIR Lv.), or 3) Hir 40 mg
bolus + 0.2 mgjkg/hr Hir iv 24 hrs + 40 mg Hir sc bid for 3 days (HIR Lv. +
s.c). All patients had unstable angina pectoris. Study treatment started just
prior to angioplasty.
Secondary endpoint: incidence of early (:s96 hrs) major adverse cardiac
events. Randomization was stratified for presence or absence of heparin pre-
treatment ("ON" vs. "OFF" heparin):
This significant effect of Angiopeptin in decreasing clinical events in pa-
tients undergoing PTCA is maintained at one year.
RAVES Non-RAVES Pvalue
Vascular/bleeding complications (%) 31 19.1 004
TransfusionlSurgical repair (%) 0/0 24.0/93 0002/0.1
Subacute thrombosis (%) 0 13 1.0
In-hospital Complieations (%): 0/0/0/0 13/0/0/13 1.0/-1-11.0
Death/MI/CABG/Repeat fTTCA
Length of stay (days) 43±20 82 ± 4.9 <0.0001
Costs ($) 8,734 ± 2,238 14,182 ± 6,938 <00001
Stent (S) placement in the treatment of saphenous vein graft (SVG) lesions
has been limited by increased bleeding complications and prolonged hos-
pital stay due to intense anticoagulation after procedure. Intravascular ultra-
sound (IVUS) guided S implantation with .B.educed 8nticoagulation (no hep-
arin or coumadin post procedure) VEin graft.§.tent trial (RAVES) was designed
to address these issues. To assess the economic impact of this novel S place-
ment technique, we compared the in-hospital complications and costs in 33
RAVES pts with 77 pts who underwent standard (Non-RAVESI S deployment
for SVG lesions. Enrollment criteria, pt demographics and pre-treatment an-
giographic findings were similar between the 2 groups. Vascular/bleeding
complications = hematoma with> 15% drop in hematocrit, A-V fistula, pseu-
doaneurysm, retroperitoneal bleed, and gastrointestinal bleed.
Conclusion: Similar to PTCA in SVG lesions and in contrast to stents in
native coronaries, patients with stents in SVG's exhibit a disappointing attri-
tion in late clinical outcomes beyond one year, Both increasing mortality and
repeat revascularization procedures contribute to the 2-year 55% event-free
survival. We surmise that further deterioration at the stent site (Le, "late"
restenosis), increasing non-TLR events, and less favorable baseline charac-
teristics are responsible for these findings.
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1710-61 Economic Impact of Reduced Anticoagulation After
Saphenous Vein Graft Stent Placement
s, Chiu Wong, Jeffrey J. Popma, Ya Chien Chuang, Gary S, Mintz, Lowell F Satler,
Kenneth M. Kent, Augusto D, Pichard, Mun K. Hong, Theresa A. Bucher,
Kathi Donovan, Kathy Morgan, Alan Merritt, David Kaufman, Martin B. Leon.
Washington Hospital Center, Washington, DC
There were no out-of-hospital ischemic complications reported up to 1
month (vulnerable period for subacute thrombosis) after procedure in both
groups.
/n Conclusion: IVUS guided S implantation with reduced anticoagulation
resulted in marked reduction in bleeding events and no increase in procedu-
ral or 30-day complications, The hospital length of stay was significantly re-
duced in the RAVES pts with substantial cost saving (38.4%) compared with
Non-RAVES pts. If this observation holds true in a larger cohort, S placemHnt
with reduced anticoagulation should be the treatment of choice for SVG le-
sions.
Adjunctive Therapy and Outcome With PTeA
Monday, March 20, 1995,2:00 p.m.-3:30 p.m.
Ernest N. Morial Convention Center, Room 102
Results HEP HIR i.v. HIR i.v. + s.c.
"ON" "OFF" "ON" "OFF" "ON" "OFF"
N= 115 267 110 271 110 269
Any Event % 174 82 64 8.5 64 52
Death % 09 04
Ml% 70 2.2 2.7 3.7 4.6 15
CABG% 70 4.5 3.6 37 18 2.2
Re-PTCA % 2.6 1.1 1.1 1.5
Conclusion: In patients with unstable angina who were receiving heparin
at the time of randomization, hirudin i.v. for 24 hours, with or without hirudin
s.c, for 72 hrs, substantially reduces the incidence of major adverse cardiac
events encountered during the first 96 hrs following PTCA, when compared
to heparin as anticoagulant (-63%,6.4% vs 17.4%, Chi square p = 0.007).
This favourable effect is obtained without a significant increase in major
bleeding complications (HEP 6.2%, HIR Lv. 5.5%, HIR Lv. + s.c. 7.6%).
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~ Angiopeptin Significantly Improves Twelve Months
Event Free Survival Following PTCA in a Randomized
Double Blind Study
H~kan Emanuelsson, Kevin J. Beatt. Jens-Peder Bagger, Raphael Balcon,
Juhani Heikkila, Jan Piessens, Marc Schaeffer, Harry Suryapranata, Marie L. Foegh,
European Angiopeptin Study Group. Henri Beaufour Institute, Washington, D.C.
Patients (n = 553) undergoing coronary balloon angioplasty in 18 European
centers were randomized to receive a five-day continuous s.c. infusion of
either placebo or Angiopeptin (6 mg/daYI beginning the day prior to PTCA.
The inclusion criteria were broad and only patients with a Q-wave infarction
within the last 4 weeks prior to PTCA were excluded. The primary endpoint
for 12 months outcome was the composite of death, non-fatal MI or repeat
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A Multicenter, Randomized, Double-Blind Pilot Trial
of Standard Versus Low Dose Weight-Adjusted
Heparin in Patients Treated with the Platelet GP
lib/ilia Receptor Antibody c7E3 During Percutaneous
Coronary Revascularization
A Michael Lincoll, James E. Tcheng, Theodore A. Bass, Jeffrey J. Popma, Paul
S. Teirstein, Neal S, Kleiman, Harlan F. Weisman, Maura H. Musco, Catherine
F Cabot, Lisa G. Berdan, Robert M. Califf, Eric J. Topol, PROLOG Investigators.
Cleveland Clinic Foundation, Cleveland, OH; Duke University, Durham, NC
Blockade olthe platelet GP lib/lila receptor by the monoclonal antibody c7E3
during high-risk coronary intervention reduced the 30-day endpoint of death,
MI, or urgent revascularization by 35% in the EPIC trial, but was accompa-
nied by an increase in the rate of major bleeding. In EPIC, heparin was ad-
